ProMIS Neurosciences

ProMIS Neurosciences EBITDA

Delisted

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ProMIS Neurosciences (PMN.TO) as of Oct 15, 2026 is -23.38 M CAD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -8.29 M CAD — a change of 181.99% (lower).

EBITDA

-23.38 MCAD

YoY

181.99%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ProMIS Neurosciences is 2022 -23.38 M CAD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ProMIS Neurosciences was 2021 -8.29 M CAD. It decreases by 181.99% lower compared to the previous year.

The ProMIS Neurosciences EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2015
-1.99 M CAD
Jan 1, 2016
-3.44 M CAD
Jan 1, 2017
-6.01 M CAD
Jan 1, 2018
-10.17 M CAD
Jan 1, 2019
-7.40 M CAD
Jan 1, 2020
-5.66 M CAD
Jan 1, 2021
-8.29 M CAD
Jan 1, 2022
-23.38 M CAD
The ProMIS Neurosciences EBITDA history
YEAREBITDAYoY
-23.38 MCAD+181.99%
-8.29 MCAD+46.49%
-5.66 MCAD-23.51%
-7.40 MCAD-27.24%
-10.17 MCAD+69.22%
-6.01 MCAD+74.71%
-3.44 MCAD+72.86%
-1.99 MCAD-7.01%
-2.14 MCAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProMIS Neurosciences Stock analysis

What does ProMIS Neurosciences do? ProMIS Neurosciences Inc is a biopharmaceutical company based in Canada that specializes in the discovery and development of novel therapeutics for neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. The company was founded in 2004 and has been listed on the Toronto Stock Exchange since 2015. The goal of ProMIS is to develop highly specific therapeutics that specifically target the cellular causes of neurodegenerative diseases and can therefore stop or even reverse the progression of the disease. The company utilizes its proprietary platform technology to identify the unique epitopes on the pathological proteins that are specific to neurodegenerative diseases. ProMIS' business model is based on partnerships with large pharmaceutical companies that are searching for new therapeutics for neurodegenerative diseases. ProMIS works closely with these partners to develop customized therapeutics tailored to each partner's specific needs. The company licenses its technology and products to its partners and receives license and milestone payments when certain development or sales goals are achieved. ProMIS has different divisions to focus on various neurodegenerative diseases, with a focus on Alzheimer's, Parkinson's, and ALS. ProMIS has a comprehensive research and development infrastructure that focuses on the identification, characterization, and optimization of therapeutic antibodies and biomarkers. In terms of products, ProMIS has developed various antibodies that specifically target pathological proteins such as Aß and Tau in Alzheimer's and alpha-synuclein in Parkinson's. These antibodies can selectively recognize and bind to these pathological proteins, allowing them to be broken down and removed from the body. ProMIS works closely with its partners to test these antibodies in clinical trials and eventually bring them to market. In addition to its antibody products, ProMIS has also developed neuromethods that allow researchers to characterize and quantify the functions of proteins in brain cells and in vivo. These methods can be used to test and optimize the effects of antibodies and other therapeutics, making them an important part of ProMIS' development infrastructure. Overall, ProMIS Neurosciences Inc is an innovative biopharmaceutical company that focuses on the development of highly specific therapeutics for neurodegenerative diseases. The company has a comprehensive infrastructure and technology platform that allows it to develop customized products for its partners. With its antibodies and neuromethods, ProMIS has the potential to make a breakthrough in the treatment of neurodegenerative diseases and improve the lives of millions of patients. ProMIS Neurosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ProMIS Neurosciences stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ProMIS Neurosciences is -23.38 M CAD in 2022.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ProMIS Neurosciences changed from -8.29 M CAD to -23.38 M CAD, representing a 181.99% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) ProMIS Neurosciences since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s ProMIS Neurosciences historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ProMIS Neurosciences

All Key Metrics — ProMIS Neurosciences